Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2008

View Archived Issues

Recent patents report novel analgesic agents

New psychopharmacologic compounds disclosed in recent patents

Plethora completes patient recruitment into phase IIb study of PSD-508 for dysmenorrhea

MorphoSys completes first dosing regimen in phase I clinical trial of MOR-103

Medarex and Bristol-Myers present update on clinical development of ipilimumab

Solvay to acquire Innogenetics for EUR 177.6 million cash

Avesthagen and ShigaMedix enter agreement for vaccines against HPV and TB

Topically administered carbonic anhydrase specific siRNA improves intraocular pressure

Independent Pharmaceutica initiates phase II clinical trial of Niccine for nicotine dependence

Roxro reports positive results from proof-of-concept clinical study of ketorolac for migraine

Aida presents update on clinical development of Rh-Apo2L for cancer

Metabasis reports positive results from phase IIa clinical trial of MB-07803 in type 2 diabetes

IRC-083927 active in cells resistant to tubulin-binding agents

Neural stem cell-mediated treatment may allow targeted 5-FU therapy for glioma

Preclincal antitumor activity of CVX-060 increased by chemotherapy agents

Pfizer presents TP-10, a PDE10A inhibitor under development for schizophrenia

New agents for treating asthma and other respiratory disorders described in recent patent literature

Cougar initiates enrollment in phase III CB-7630 trial in prostate cancer

Merck receives not approvable letter from FDA for MK-0524A

Positive proof-of-concept data reported for Nuvelo's anticogulant NU-172

Orexo reports results from phase I study of OX-19 nasal spray for incontinence

KaloBios completes dosing in U.S. phase I clinical trial of monoclonal antibody KB-003

Inhibitex initiates phase I clinical trial of oral nucleoside analogue FV-100 for shingles

Cytokinetics commences second phase IIa CK-1827452 trial

Sucampo obtains FDA approval for Amitiza for IBS with constipation in adult women

Peregrine completes enrollment in first stage of phase II trial of bavituximab in breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...